000128776 001__ 128776
000128776 005__ 20240228143347.0
000128776 0247_ $$2doi$$a10.1186/s12859-016-1183-6
000128776 0247_ $$2pmid$$apmid:27578050
000128776 0247_ $$2pmc$$apmc:PMC5004308
000128776 0247_ $$2altmetric$$aaltmetric:10909583
000128776 037__ $$aDKFZ-2017-04791
000128776 041__ $$aeng
000128776 082__ $$a004
000128776 1001_ $$00000-0002-1810-9149$$aHieke, Stefanie$$b0
000128776 245__ $$aIntegrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information.
000128776 260__ $$aLondon$$bBioMed Central$$c2016
000128776 3367_ $$2DRIVER$$aarticle
000128776 3367_ $$2DataCite$$aOutput Types/Journal article
000128776 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522055462_13173
000128776 3367_ $$2BibTeX$$aARTICLE
000128776 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128776 3367_ $$00$$2EndNote$$aJournal Article
000128776 520__ $$aHigh-throughput technology allows for genome-wide measurements at different molecular levels for the same patient, e.g. single nucleotide polymorphisms (SNPs) and gene expression. Correspondingly, it might be beneficial to also integrate complementary information from different molecular levels when building multivariable risk prediction models for a clinical endpoint, such as treatment response or survival. Unfortunately, such a high-dimensional modeling task will often be complicated by a limited overlap of molecular measurements at different levels between patients, i.e. measurements from all molecular levels are available only for a smaller proportion of patients.We propose a sequential strategy for building clinical risk prediction models that integrate genome-wide measurements from two molecular levels in a complementary way. To deal with partial overlap, we develop an imputation approach that allows us to use all available data. This approach is investigated in two acute myeloid leukemia applications combining gene expression with either SNP or DNA methylation data. After obtaining a sparse risk prediction signature e.g. from SNP data, an automatically selected set of prognostic SNPs, by componentwise likelihood-based boosting, imputation is performed for the corresponding linear predictor by a linking model that incorporates e.g. gene expression measurements. The imputed linear predictor is then used for adjustment when building a prognostic signature from the gene expression data. For evaluation, we consider stability, as quantified by inclusion frequencies across resampling data sets. Despite an extremely small overlap in the application example with gene expression and SNPs, several genes are seen to be more stably identified when taking the (imputed) linear predictor from the SNP data into account. In the application with gene expression and DNA methylation, prediction performance with respect to survival also indicates that the proposed approach might work well.We consider imputation of linear predictor values to be a feasible and sensible approach for dealing with partial overlap in complementary integrative analysis of molecular measurements at different levels. More generally, these results indicate that a complementary strategy for integrating different molecular levels can result in more stable risk prediction signatures, potentially providing a more reliable insight into the underlying biology.
000128776 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128776 588__ $$aDataset connected to CrossRef, PubMed,
000128776 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b1$$udkfz
000128776 7001_ $$aSchlenl, Richard F$$b2
000128776 7001_ $$aSchumacher, Martin$$b3
000128776 7001_ $$aBullinger, Lars$$b4
000128776 7001_ $$aBinder, Harald$$b5
000128776 773__ $$0PERI:(DE-600)2041484-5$$a10.1186/s12859-016-1183-6$$gVol. 17, no. 1, p. 327$$n1$$p327$$tBMC bioinformatics$$v17$$x1471-2105$$y2016
000128776 909CO $$ooai:inrepo02.dkfz.de:128776$$pVDB
000128776 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128776 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128776 9141_ $$y2016
000128776 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC BIOINFORMATICS : 2015
000128776 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128776 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128776 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128776 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000128776 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000128776 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000128776 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128776 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128776 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128776 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128776 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128776 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128776 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128776 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128776 980__ $$ajournal
000128776 980__ $$aVDB
000128776 980__ $$aI:(DE-He78)C060-20160331
000128776 980__ $$aUNRESTRICTED